Send to printer »

GEN News Highlights : Jan 11, 2007

Court Permanently Halts Abbott's Sale of HCV Genotyping Products for Infringing Innogenetics' Patent

Permanent injunction covers sale, use, and export of products and components.

Innogenetics reported that a U.S. court entered a permanent injunction against Abbott Laboratories, prohibiting the company from selling or using products, including components, that infringe on Innogenetics' patented Hepatitis C Virus  genotyping technology. The injunction also prevents Abbott from exporting components of the infringing products to foreign countries.

In September 2006 a jury unanimously found that Abbott had willfully infringed Innogenetics' U.S. patent 5,846,704 and awarded the company $7 million in damages.

The U.S. District Court for the Western District of Wisconsin made the ruling at the close of an evidentiary hearing to determine the potential public impact of a permanent injunction against Abbott. Last week, the court found that Innogenetics suffered irreparable harm from Abbott's infringement.